Chloroquine resistance arises primarily from mutations affecting the parasite’s digestive vacuole, the site of chloroquine action. Specifically, mutations in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene are key. These mutations alter the protein’s structure, reducing chloroquine accumulation within the vacuole. This impaired uptake directly diminishes the drug’s efficacy.
Pfcrt Gene Mutations and Their Impact
Mutations at positions 76, 72, 97, 100, 218 and 271 of pfcrt are strongly associated with chloroquine resistance. The K76T mutation, for instance, is particularly significant. It enhances the protein’s ability to export chloroquine from the vacuole, lowering intracellular drug concentrations. Other mutations contribute additively or synergistically, boosting resistance levels further. Detailed studies mapping these mutations and their functional consequences are crucial for developing resistance-breaking strategies.
Beyond pfcrt: Other Contributing Factors
While pfcrt mutations are the most prominent, other factors contribute to chloroquine resistance. Changes in the heme detoxification pathway, a process chloroquine interferes with, can influence resistance levels. Increased expression of the pfmdr1 gene, encoding a multidrug resistance transporter, is also implicated, facilitating the efflux of chloroquine and other drugs.
Therefore, a multifactorial approach is needed to comprehensively understand and combat chloroquine resistance. Studying these intricate interactions between genetic factors and physiological processes will drive the development of future antimalarial therapies.
